Heron Therapeutics Inc (HRTX)

Healthcare Pharmaceuticals & Medical Research Biotechnology & Medical Research

Track Share on 𝕏

Stock chart
Ticker: HRTX Exchange: NAS


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale
Past 90 days
 
Value bought
 
Value sold
 
Net insiders buying
 
Trades (buy and sell)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Total value Details
2023-11-21 2023-11-17 B Purchase

Forbes William P

EVP, Chief Development Officer

Officer
25,000 +46.3%
1.09
27,250 USD 		25,000 +46.3% 1.09 27,250 USD
2023-11-20 2023-11-16 B Purchase

Forbes William P

EVP, Chief Development Officer

Officer
50,000 +1250.0%
0.94
46,995 USD 		50,000 +1250.0% 0.94 46,995 USD
2023-11-17 2023-11-16 B Purchase

Collard Craig A

Chief Executive Officer

Executive Director
150,000 +411.0%
0.92
137,970 USD 		150,000 +411.0% 0.92 137,970 USD
2023-11-17 2023-11-16 B Purchase

Duarte Ira

EVP, Chief Financial Officer

Officer
85,000 +inf%
0.89
75,599 USD 		85,000 +inf% 0.89 75,599 USD
2023-07-25 2023-07-21 B Purchase

Morgan Adam

Non-Executive Director
2,486,744 +55.3%
1.37
3,406,839 USD 		2,486,744 +55.3% 1.37 3,406,839 USD
2022-05-04 2022-05-03 PS Planned sale

MANHARD KIMBERLY

EVP, Drug Development

Executive Director
1,504 -12.2%
4.76
7,154 USD 		1,504 -12.2% 4.76 7,154 USD
2021-12-23 2021-12-21 PS Planned sale

Johnson Craig A

Non-Executive Director
250 -8.1%
9.73
2,432 USD 		250 -8.1% 9.73 2,432 USD
2021-12-23 2021-12-21 PS Planned sale

Christian Waage

Non-Executive Director
300 -8.6%
9.73
2,920 USD 		300 -8.6% 9.73 2,920 USD
2021-06-22 2021-06-21 PS Planned sale

Christian Waage

Non-Executive Director
300 -7.3%
15.20
4,559 USD 		300 -7.3% 15.20 4,559 USD
2021-06-22 2021-06-21 PS Planned sale

Johnson Craig A

Non-Executive Director
250 -7.0%
15.20
3,801 USD 		250 -7.0% 15.20 3,801 USD
2021-04-16 2021-04-15 PS Planned sale

Christian Waage

Non-Executive Director
300 -6.8%
17.51
5,254 USD 		300 -6.8% 17.51 5,254 USD
2021-04-07 2021-04-06 PS Planned sale

Johnson Craig A

Non-Executive Director
250 -6.5%
17.22
4,305 USD 		250 -6.5% 17.22 4,305 USD
2021-01-15 2021-01-14 PS Planned sale

Szekeres David Leslie

EVP, Chief Operating Officer

Officer
827 -100.0%
18.09
14,960 USD 		827 -100.0% 18.09 14,960 USD
2021-01-08 2021-01-08 PS Planned sale

Szekeres David Leslie

EVP, Chief Operating Officer

Officer
3,571 -100.0%
19.66
70,219 USD 		3,571 -100.0% 19.66 70,219 USD
2020-12-23 2020-12-22 PS Planned sale

MANHARD KIMBERLY

EVP, Drug Development

Executive Director
10,000 -100.0%
20.00
200,000 USD 		10,000 -100.0% 20.00 200,000 USD
2020-05-01 2020-05-01 PS Planned sale

MANHARD KIMBERLY

Executive VP, Drug Development

Executive Director
1,158 -100.0%
13.97
16,176 USD 		1,158 -100.0% 13.97 16,176 USD
2019-12-03 2019-11-29 PS Planned sale

MANHARD KIMBERLY

Executive VP, Drug Development

Executive Director
24,000 -100.0%
26.00
624,000 USD 		24,000 -100.0% 26.00 624,000 USD
2019-10-07 2019-10-04 B Purchase

TANG KEVIN C

285,714 +5.2%
17.50
4,999,995 USD 		285,714 +5.2% 17.50 4,999,995 USD
2019-10-04 2019-10-03 B Purchase

Quart Barry D

Chief Executive Officer

Executive Director
4,571 +5.1%
17.50
79,993 USD 		4,571 +5.1% 17.50 79,993 USD
2019-10-04 2019-10-03 B Purchase

POYHONEN JOHN

EVP, Chief Commercial Officer

Executive Director
5,143 +39.6%
17.50
90,003 USD 		5,143 +39.6% 17.50 90,003 USD
2019-05-23 2019-05-22 B Purchase

POYHONEN JOHN

Non-Executive Director
3,000 +30.0%
17.55
52,650 USD 		3,000 +30.0% 17.55 52,650 USD
2019-05-16 2019-05-15 B Purchase

Christian Waage

1,400 +inf%
18.04
25,262 USD 		1,400 +inf% 18.04 25,262 USD
2019-05-02 2019-05-01 PS Planned sale

MANHARD KIMBERLY

Executive VP, Drug Development

Officer
1,109 -100.0%
18.86
20,918 USD 		1,109 -100.0% 18.86 20,918 USD
2018-11-02 2018-11-02 PS Planned sale

MANHARD KIMBERLY

Executive VP, Drug Development

Officer
494 -100.0%
30.62
15,125 USD 		494 -100.0% 30.62 15,125 USD
2018-10-02 2018-10-01 PS Planned sale

MANHARD KIMBERLY

Executive VP, Drug Development

Officer
6,000 -100.0%
32.07
192,433 USD 		6,000 -100.0% 32.07 192,433 USD
2018-09-12 2018-09-12 S Sale

TANG KEVIN C

Non-Executive Director Major owner
2,695,000 -31.6%
35.75
96,346,250 USD 		2,695,000 -31.6% 35.75 96,346,250 USD
2018-07-03 2018-07-02 PS Planned sale

Rosen Robert

President

Executive Director
3,400 -56.3%
38.75
131,765 USD 		3,400 -56.3% 38.75 131,765 USD
2018-07-03 2018-07-02 PS Planned sale

Rosen Robert

President

Executive Director
92,131 -93.8%
38.13
3,512,918 USD 		92,131 -93.8% 38.13 3,512,918 USD
2018-07-03 2018-07-02 PS Planned sale

MANHARD KIMBERLY

Executive VP, Drug Development

Officer
100 -100.0%
38.85
3,885 USD 		100 -100.0% 38.85 3,885 USD
2018-07-03 2018-07-02 PS Planned sale

MANHARD KIMBERLY

Executive VP, Drug Development

Officer
5,900 -98.3%
37.51
221,294 USD 		5,900 -98.3% 37.51 221,294 USD
2018-07-03 2018-07-02 PS Planned sale

HOFFMAN ROBERT

CFO & SVP, Finance

Officer
1,060 -45.3%
38.80
41,123 USD 		1,060 -45.3% 38.80 41,123 USD
2018-07-03 2018-07-02 PS Planned sale

HOFFMAN ROBERT

CFO & SVP, Finance

Officer
28,940 -92.5%
38.15
1,104,107 USD 		28,940 -92.5% 38.15 1,104,107 USD
2018-07-03 2018-06-29 PS Planned sale

Rosen Robert

President

Executive Director
2,112 -44.4%
41.39
87,415 USD 		2,112 -44.4% 41.39 87,415 USD
2018-07-03 2018-06-29 PS Planned sale

Rosen Robert

President

Executive Director
51,696 -91.6%
40.17
2,076,597 USD 		51,696 -91.6% 40.17 2,076,597 USD
2018-07-03 2018-06-29 PS Planned sale

Rosen Robert

President

Executive Director
75,661 -57.3%
39.14
2,961,122 USD 		75,661 -57.3% 39.14 2,961,122 USD
2018-06-22 2018-06-21 PS Planned sale

Quart Barry D

Chief Executive Officer

Executive Director
50,000 -41.8%
39.05
1,952,500 USD 		50,000 -41.8% 39.05 1,952,500 USD
2018-04-02 2018-03-29 B Purchase

TANG KEVIN C

Major owner
192,308 +2.3%
26.00
5,000,008 USD 		192,308 +2.3% 26.00 5,000,008 USD
2018-03-19 2018-03-19 PS Planned sale

MANHARD KIMBERLY

Executive VP, Drug Development
18,000 -100.0%
30.00
540,000 USD 		18,000 -100.0% 30.00 540,000 USD
2018-03-19 2018-03-19 PS Planned sale

Quart Barry D

Chief Executive Officer

Executive Director
100,000 -59.5%
29.75
2,975,000 USD 		100,000 -59.5% 29.75 2,975,000 USD
2018-03-16 2018-03-14 PS Planned sale

Quart Barry D

Chief Executive Officer

Executive Director
100,000 -59.5%
24.75
2,475,000 USD 		100,000 -59.5% 24.75 2,475,000 USD
2018-01-12 2018-01-10 PS Planned sale

MANHARD KIMBERLY

Executive VP, Drug Development

Officer
7,584 -100.0%
20.00
151,680 USD 		7,584 -100.0% 20.00 151,680 USD
2017-04-24 2017-04-24 PS Planned sale

MANHARD KIMBERLY

Executive VP, Drug Development
21,542 -100.0%
15.33
330,263 USD 		21,542 -100.0% 15.33 330,263 USD
2017-01-23 2017-01-19 B Purchase

POYHONEN JOHN

10,000 +inf%
12.20
122,000 USD 		10,000 +inf% 12.20 122,000 USD
2017-01-23 2017-01-19 B Purchase

TANG KEVIN C

Non-Executive Director Major owner
2,459,016 +41.9%
12.20
29,999,995 USD 		2,459,016 +41.9% 12.20 29,999,995 USD
2016-08-12 2016-08-10 PS Planned sale

Rosen Robert

President & CCO

Executive Director
12,400 -82.4%
23.89
296,278 USD 		12,400 -82.4% 23.89 296,278 USD
2016-08-12 2016-08-10 PS Planned sale

Rosen Robert

President & CCO

Executive Director
87,600 -85.3%
23.21
2,033,616 USD 		87,600 -85.3% 23.21 2,033,616 USD
2016-04-21 2016-04-21 PS Planned sale

Rosen Robert

President

Executive Director
19,662 -88.2%
22.15
435,433 USD 		19,662 -88.2% 22.15 435,433 USD
2016-04-21 2016-04-20 PS Planned sale

Rosen Robert

President

Executive Director
4,010 -60.3%
22.19
88,967 USD 		4,010 -60.3% 22.19 88,967 USD
2016-04-21 2016-04-19 PS Planned sale

Rosen Robert

President

Executive Director
6,230 -70.2%
25.11
156,438 USD 		6,230 -70.2% 25.11 156,438 USD
2016-04-21 2016-04-19 PS Planned sale

Rosen Robert

President

Executive Director
32,224 -78.4%
24.49
789,037 USD 		32,224 -78.4% 24.49 789,037 USD
2016-04-21 2016-04-19 PS Planned sale

Rosen Robert

President

Executive Director
76,949 -65.2%
23.47
1,805,955 USD 		76,949 -65.2% 23.47 1,805,955 USD
2016-04-21 2016-04-19 PS Planned sale

Rosen Robert

President

Executive Director
60,925 -34.0%
22.50
1,370,593 USD 		60,925 -34.0% 22.50 1,370,593 USD
2015-06-12 2015-06-10 B Purchase

TANG KEVIN C

Non-Executive Director Major owner
121,212 +2.6%
24.75
2,999,997 USD 		121,212 +2.6% 24.75 2,999,997 USD
2015-06-03 2015-06-02 S Sale

MANHARD KIMBERLY

Non-Executive Director
10,500 -100.0%
23.58
247,590 USD 		10,500 -100.0% 23.58 247,590 USD
2015-06-02 2015-06-02 B Purchase

TANG KEVIN C

Non-Executive Director Major owner
32,395 +0.7%
23.84
772,294 USD 		32,395 +0.7% 23.84 772,294 USD
2015-06-03 2015-06-01 S Sale

MANHARD KIMBERLY

Non-Executive Director
2,708 -100.0%
21.17
57,328 USD 		2,708 -100.0% 21.17 57,328 USD
2015-06-02 2015-06-01 B Purchase

TANG KEVIN C

Non-Executive Director Major owner
2,380 +0.1%
19.30
45,934 USD 		2,380 +0.1% 19.30 45,934 USD
2015-06-02 2015-05-29 B Purchase

TANG KEVIN C

Non-Executive Director Major owner
115,225 +2.5%
19.74
2,274,058 USD 		115,225 +2.5% 19.74 2,274,058 USD
2015-03-09 2015-03-05 PS Planned sale

Marshall Paul

SVP, Technical Operations

Officer
20,000 -100.0%
15.40
308,000 USD 		20,000 -100.0% 15.40 308,000 USD
2015-03-09 2015-03-05 PS Planned sale

Marshall Paul

SVP, Technical Operations

Officer
50,000 -71.4%
14.40
720,000 USD 		50,000 -71.4% 14.40 720,000 USD
2014-06-27 2014-06-25 B Purchase

TANG KEVIN C

Non-Executive Director Major owner
510,638 +12.5%
11.75
5,999,997 USD 		510,638 +12.5% 11.75 5,999,997 USD
2014-06-26 2014-06-25 B Purchase

Quart Barry D

Chief Executive Officer

Executive Director
10,000 +19.3%
11.75
117,500 USD 		10,000 +19.3% 11.75 117,500 USD
2013-11-21 2013-11-20 B Purchase

Quart Barry D

Chief Executive Officer

Executive Director
1,000,000 +2695.4%
0.40
400,000 USD 		1,000,000 +2695.4% 0.40 400,000 USD
2012-09-12 2012-07-25 B Purchase

SPCH, LLLP

Major owner
38,095,238 +inf%
0.53
20,000,000 USD 		38,095,238 +inf% 0.53 20,000,000 USD
2009-10-21 2009-10-19 B Purchase

TANG KEVIN C

Non-Executive Director Major owner
2,443,181 +30.6%
0.88
2,149,999 USD 		2,443,181 +30.6% 0.88 2,149,999 USD
2009-01-05 2008-12-31 B Purchase

TANG KEVIN C

Major owner
175,000 +2.2%
0.42
72,625 USD 		175,000 +2.2% 0.42 72,625 USD
2008-12-22 2008-12-18 B Purchase

TANG KEVIN C

Major owner
415,300 +5.6%
0.48
200,673 USD 		415,300 +5.6% 0.48 200,673 USD
2008-11-17 2008-11-13 B Purchase

TANG KEVIN C

Major owner
775,032 +11.7%
0.48
372,015 USD 		775,032 +11.7% 0.48 372,015 USD
2008-11-17 2008-11-13 B Purchase

TANG KEVIN C

Major owner
66,000 +1.0%
0.50
32,710 USD 		66,000 +1.0% 0.50 32,710 USD
2008-11-12 2008-11-10 S Sale

ROSENBLATT TOBY

Non-Executive Director
40,000 -100.0%
0.51
20,524 USD 		40,000 -100.0% 0.51 20,524 USD
2008-11-12 2008-11-10 S Sale

ROSENBLATT TOBY

Non-Executive Director
6,881 -18.5%
0.51
3,531 USD 		6,881 -18.5% 0.51 3,531 USD
2008-11-04 2008-10-31 B Purchase

TANG KEVIN C

Major owner
336,300 +5.4%
0.61
204,067 USD 		336,300 +5.4% 0.61 204,067 USD
2008-10-14 2008-10-10 B Purchase

TANG KEVIN C

Major owner
870,000 +16.2%
0.74
647,019 USD 		870,000 +16.2% 0.74 647,019 USD
2008-10-02 2008-09-30 B Purchase

TANG KEVIN C

Major owner
650,000 +13.8%
0.97
627,900 USD 		650,000 +13.8% 0.97 627,900 USD
2008-08-06 2008-08-01 B Purchase

PRENTKI RONALD J

President & CEO

Executive Director
1,200 +181.8%
1.42
1,704 USD 		1,200 +181.8% 1.42 1,704 USD